Compare Modine Manufacturing Company (MOD) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

Modine Manufacturing (MOD) trades at $192.35, down 1.19% on the day, with a bearish technical signal despite strong analyst support. The company shows robust revenue growth driven by data center cooling demand, with Q2 2026 EPS beating estimates at $1.53 versus $1.30 expected. However, valuation metrics appear stretched with a P/E of 71.77 and EV/EBITDA of 35.15, while profit margins face pressure from supply chain constraints.

The outlook remains positive due to strong data center backlog growth and analyst consensus price target of $305, representing 59% upside potential. Key risks include execution challenges in scaling production and margin compression. With 77% of analysts rating MOD as Buy and no Sell ratings, Wall Street maintains bullish sentiment despite near-term volatility.

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.